AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03808545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIPAMS + Diet
Description: For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
Study NCT00517998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
Description: 10 mL Hydrogel
Study NCT02531906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO
Study NCT02531906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Given PO
Study NCT02531906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Given PO
Study NCT02531906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02531906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03229278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme Inhibitor Therapy
Description: Given trigriluzole PO
Study NCT03327792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Description: 200 mg Mavoglurant
Study NCT03229278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03229278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03229278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04271137 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 3D printed PEEK onlay
Description: 3d computer-designed Orbital onlay
Study NCT04271137 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pre-bent orbital mesh
Description: Pre-bent orbital mesh on 3d printed template
Study NCT03474913 — intervention group
Intervention type: DEVICE
Intervention: Upright MRI
Description: Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
Study NCT01171976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
Study NCT01171976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
Study NCT03474913 — intervention group
Intervention type: DEVICE
Intervention: Standard MRI
Description: standard of care closed 3T MRI
Study NCT02456753 — intervention group
Intervention type: DEVICE
Intervention: trans-perineal ultrasonography
Description: Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
Study NCT06421714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study NCT06421714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study NCT05175131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebeverine+Simethicone
Description: fixed-dose combination, film-coated tablets, 135 mg + 80 mg
Study NCT05175131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebeverine
Description: Duspatalin®, coated tablets 135 mg
Study NCT05175131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: Espumisan® capsules 40 mg
Study NCT02858440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
Study NCT01140867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: zonisamide 100 mg tablet
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 30 mg
Description: A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 60 mg
Description: A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 120 mg
Description: A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg (Treatment A)
Description: 1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 60 mg (Treatment B and part of Treatment C and D)
Description: 2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 100 mg (part of Treatment C)
Description: 1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Study NCT02018536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg (part of treatment D)
Description: 1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Study NCT03617536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.25 mg Oral Tablet
Description: CR845 0.25 mg medication taken orally 1 time/day
Study NCT03617536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mg Oral Tablet
Description: CR845 0.5 mg medication taken orally 1 time/day
Study NCT02958800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A.
Study NCT00940069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
Study NCT04030585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
Study NCT03327792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04030585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
Study NCT03067948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Designated Positive Screen Shared with Provider
Description: Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
Study NCT04000516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Restricting the eating window to about 8 hours a day, during waking hours.
Study NCT01796912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoprotein Apheresis
Description: Weekly lipoprotein apheresis for 3 months
Study NCT01796912 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Apheresis
Description: Weekly sham (placebo) apheresis for 3 months
Study NCT00951496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00951496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00951496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP
Study NCT00951496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP
Study NCT00951496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00951496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00951496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP
Study NCT00951496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03908060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One intravenous administration of methadone (0.2 mg/kg ideal body weight)
Study NCT03908060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One intravenous administration of morphine (0.2 mg/kg ideal body weight)
Study NCT04027439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part A: RPL554
Description: 1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
Study NCT03617536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1 mg Oral Tablet
Description: CR845 1 mg medication taken orally 1 time/day
Study NCT03617536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken orally 1 time/day
Study NCT02429193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone + prednisone
Description: Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
Study NCT02429193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide (160 mg/day p.o.)
Study NCT02325570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic OraLum Gel
Description: Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
Study NCT03602638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100mg QD
Study NCT03602638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose
Study NCT02482389 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single fraction of 7 Gy
Description: All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
Study NCT00407420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandometer
Description: A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
Study NCT00407420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandometer
Description: A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
Study NCT00407420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Typical dietary and activity advice as normally provided in clinic (control).
Study NCT00879788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10mg capsules
Study NCT00879788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10mg capsules
Study NCT04027439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part B: RPL554
Description: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
Study NCT04027439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Study NCT01693289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin plus letrozole
Study NCT01693289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian drilling
Study NCT02261402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisinstart
Description: Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
Study NCT00604357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD 25 mAb, Sirolimus, MMF
Description: Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter).
Study NCT06267495 — intervention group
Intervention type: PROCEDURE
Intervention: Epithelium-on corneal cross-linking (epi-on CXL)
Description: In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
Study NCT03814525 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
Study NCT03814525 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
Study NCT04645836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New management mode
Description: New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use
Study NCT03055559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Globifer Forte
Study NCT04564365 — intervention group
Intervention type: DRUG
Intervention: beta-blocker
Description: To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
Study NCT02550951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography
Study NCT02712060 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00721630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, lapatinib
Description: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
Study NCT02123082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz single Lumen Ureteroscope
Description: Single lumen, flexible scope for ureteroscopies
Study NCT02123082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Storz single Lumen Ureteroscope
Description: Single lumen, flexible scope for ureteroscopies
Study NCT02123082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Lumen Ureteroscope
Description: Dual lumen, flexible scope for ureteroscopies
Study NCT02123082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Lumen Ureteroscope
Description: Dual lumen, flexible scope for ureteroscopies
Study NCT01046786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
Study NCT01046786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 30 mg/kg methylprednisolone
Study NCT01046786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: oral lithium, titrated to maintain 0.6-1.0 mM serum level
Study NCT00492024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin - 400 mg once a day for 5 days
Study NCT00492024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 380 mg Microcrystalline Cellulose
Study NCT01399567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
Study NCT01399567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm
Description: The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
Study NCT01085201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Given as an infusion
Study NCT02531750 — intervention group
Intervention type: OTHER
Intervention: Immobilization due to an Achilles tendon rupture
Study NCT00201409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by slow intravenous infusion once daily for 14 days.
Study NCT00201409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
Study NCT03309995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lozenges
Description: The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
Study NCT03309995 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: Placebo lozenges
Study NCT03173326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
Study NCT03173326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.